Open AccessDiscontinuation of anti‐arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation
Author(s) -
Inoue Koichi,
Kurotobi Toshiya,
Ito Hiroshi,
Kimura Ryusuke,
Toyoshima Yuko,
Itoh Norihisa,
Higuchi Yoshiharu,
Date Motoo,
Koyama Yasushi,
Iwakura Katsuomi,
Fujii Kenshi
Publication year - 2012
Publication title -
journal of arrhythmia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 21
eISSN - 1883-2148
pISSN - 1880-4276
DOI - 10.1016/j.joa.2011.12.005
Subject(s) - bepridil , medicine , discontinuation , atrial fibrillation , catheter ablation , sinus rhythm , cardiology , atrial tachycardia , ablation , atenolol , tachycardia , anesthesia , incidence (geometry) , verapamil , blood pressure , calcium , physics , optics
Background Anti‐arrhythmic drugs (AADs) are often administered following catheter ablation (CA) for persistent atrial fibrillation (peAF) to maintain sinus rhythm (SR). It remains unclear whether AADs can be withdrawn in patients showing no recurrence after CA. Method We administered hybrid therapy consisting of CA and AAD (bepridil) in 75 patients with peAF. Withdrawal of AADs was attempted in patients who had no recurrence of AF for ≥6 months. We followed them for 22±16 months. Results Patients received 1.2±0.4 sessions of CA and a mean bepridil dose of 131±46 mg/day. After a 3‐month “blanking period,” 62 (83%) patients maintained SR without recurrence of tachyarrhythmia for ≥6 months. AADs were discontinued in 41 patients who agreed to medication withdrawal. Ten of these (24%) experienced a relapse of tachycardia, and these patients had a higher incidence of residual inducibility of tachyarrhythmia at the end of the CA procedure (70% vs. 32%; P =0.03) and required a higher dose of bepridil to maintain SR (170±48 mg vs. 106±30 mg; P <0.0001) than those without relapse. Conclusions Discontinuation of AADs occasionally results in recurrence, especially in patients with residual inducibility and in those requiring higher doses of AADs.